WVP
GCVRZ

Worth Venture Partners’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Worth Venture Partners’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-28,979
Closed -$15K – 129
2019
Q2 		$15K Hold
28,979
– – 0.01% 88
2019
Q1 		$13K Buy
28,979
+1,944
+7% +$907 0.01% 90
2018
Q4 		$12K Buy
27,035
+22
+0.1% +$11 0.01% 86
2018
Q3 		$14K Buy
+27,013
New +$14.5K 0.01% 157

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return

Worth Venture Partners's GCVRZ Position: Q3 2019 in Review

Worth Venture Partners sold out of Sanofi Contingent Value Rights (GCVRZ) in Q3 2019, closing a stake of 28,979 shares — an estimated $15K sold.

Worth Venture Partners first reported a position in GCVRZ in Q3 2018 and held it in 4 quarters. The position peaked at $15K in Q2 2019. 103 funds tracked by Wall St. Rank hold GCVRZ as of Q3 2019.

  • Worth Venture Partners reported no remaining Sanofi Contingent Value Rights position as of Q3 2019 after selling out during the quarter.
  • Worth Venture Partners sold 28,979 Sanofi Contingent Value Rights shares in Q3 2019, an estimated $15K.
  • Worth Venture Partners first reported a position in Sanofi Contingent Value Rights in Q3 2018 and held it in 4 quarters.
  • Worth Venture Partners's Sanofi Contingent Value Rights position peaked at $15K in Q2 2019.
  • 103 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q3 2019.

Based on Worth Venture Partners's 13F filing for Q3 2019, filed 12 Nov 2019.